PGEN · XBRL financial data

Precigen financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (PGEN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	103	104	27	6	4	10
Research and development	—	—	—	49	53	41
Selling, general and administrative	—	—	—	40	41	70
Total operating expenses	—	—	—	106	139	120
Operating income (loss)	—	—	—	(100)	(135)	(111)
Interest expense	—	—	—	0	0	4
Other income (expense)	—	—	—	1	9	0
Income tax expense (benefit)	(0)	(0)	(0)	(0)	(2)	0
Net income (loss)	(171)	(92)	28	(96)	(126)	(251)
Earnings per share, basic USD per share	(1.02)	(0.47)	0.14	(0.39)	(0.47)	(1.37)
Earnings per share, diluted USD per share	(1.02)	(0.47)	0.14	(0.39)	(0.47)	(1.37)
Weighted average shares, basic millions of shares	167	198	200	245	268	313
Weighted average shares, diluted millions of shares	167	198	200	245	268	313

Fiscal years (PGEN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	52	43	5	8	30	30
Short-term investments	48	72	51	55	68	68
Marketable securities, non-current	0	49	0	—	0	3
Accounts receivable	16	21	1	1	1	4
Prepaid and other current assets	7	7	5	4	3	3
Total current assets	149	157	118	69	102	115
Property and equipment, net	35	34	7	7	14	14
Right-of-use asset	9	11	8	7	5	5
Goodwill	54	54	37	27	19	15
Total assets	315	360	216	151	145	156
Accounts payable	5	5	4	2	4	12
Current portion of long-term debt	0	0	43	—	—	—
Total current liabilities	42	35	79	23	22	37
Long-term debt	172	183	0	—	0	93
Lease liability, non-current	8	10	7	6	5	4
Total liabilities	247	253	90	33	79	135
Accumulated deficit	(1,823)	(1,916)	(1,869)	(1,964)	(2,091)	(2,341)
Total stockholders' equity	67	107	126	118	39	21
Total liabilities and equity	315	360	216	151	145	156
Common shares outstanding (cover page) millions of shares	206	207	252	249	294	354

Fiscal years (PGEN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(171)	(92)	28	(96)	(126)	(251)
Stock-based compensation	18	14	10	10	9	11
Depreciation and amortization	18	14	11	7	5	3
Net cash from operating activities	(77)	(56)	(65)	(67)	(68)	(88)
Purchases of property and equipment	8	7	5	2	9	2
Net cash from investing activities	28	(75)	226	(3)	(21)	(2)
Proceeds from issuing common stock	—	—	0	73	31	(0)
Proceeds from long-term debt	0	0	—	0	0	93
Repayments of long-term debt	0	0	155	43	0	0
Net cash from financing activities	33	121	(155)	30	111	90
Net change in cash	(16)	(9)	5	(41)	22	1

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Precigen	15	74	12*	358.5M	—	Q3 FY26 10-QSep 30, 2026
SELLAS Life Sciences Group	138	not reported	(7.6)*	201.9M	18.2 quarters	Q2 FY26 10-QJun 30, 2026
Lifecore Biomedical	23	25	6.9*	37.9M	—	Q3 FY26 10-QSep 30, 2026
Perspective Therapeutics	48	not reported	(21)*	114.2M	11.5 quarters	Q2 FY26 10-QJun 30, 2026
Rocket Pharmaceuticals	225	0	(40)*	109.8M	7.2 quarters	Q2 FY26 10-QJun 30, 2026
Natures Sunshine Products	89	117	11*	17.3M	—	Q3 FY26 10-QSep 30, 2026
Sagimet Biosciences	166	not reported	(11)*	not reported	21.6 quarters	Q2 FY26 10-QJun 30, 2026
Avadel Pharmaceuticals	80	77	22*	97.7M	—	Q3 FY25 10-QSep 30, 2025
Aldeyra Therapeutics	45	not reported	(4.6)*	60.3M	9.8 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.